Company: ZLAB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038548
Chunk: 35

Company: Zai Lab Ltd
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
29 Acquisition of intangible assets(3,621)(12,168)Net cash provided by investing activities323,211 2,446 Cash flows from financing activities  Proceeds from short-term debt124,349 70,526 Repayment of short-term bank borrowings (82,818)— Payments of debt issuance costs(104)(700)Proceeds from exercises of stock options11,444 44 Payments of public offering costs(854)— Employee taxes paid related to net share settlement of equity awards(27)— Net cash provided by financing activities51,990 69,870 Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash125 (137)Net increase (decrease) in cash, cash equivalents and restricted cash282,603 (60,100)Cash, cash equivalents and restricted cash - beginning of period550,781 791,264 Cash, cash equivalents and restricted cash - end of period833,384 731,164 Supplemental disclosure on non-cash investing and financing activities  Payables for purchase of property and equipment2,498 2,391 Payables for acquisition of intangible assets2,419 32,525 Payables for public offering costs168 — Right-of-use asset acquired under operating leases— 2,389 Receivables for stock option exercise under equity incentive plans77 — Supplemental disclosure of cash flow information  Cash paid for interest2,301 496 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

7

Zai Lab Limited Notes to the unaudited condensed consolidated financial statements 

1. Organization and Principal Activities 

Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. 

The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States. 

2. Basis of Presentation and Consolidation and Significant Accounting Policies 

(a) Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U